Edgewise’s recent business highlights from 2024 include advances in their clinical trials in both Duchenne and Becker

CureDuchenne provided early funding to Edgewise Therapeutics, and we are pleased with their progress as recently shared in their fourth quarter and full year 2024 reports.  In Becker muscular dystrophy, they have completed enrollment in their pivotal GRAND CANYON trial, and are advancing a Phase 2 open label extension trial (MESA) for long-term follow up.  In Duchenne, both the LYNX and FOX Phase 2 trials are ongoing.  The programs in both Duchenne and Becker are studying the safety and efficacy of the experimental therapeutic Sevasemten, which is a fast skeletal myosin inhibitor designed to protect muscle against contraction-induced muscle damage. 

Link to press release:  https://investors.edgewisetx.com/news/news-details/2025/Edgewise-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Business-Highlights/default.aspx